Menu Search
Equities

Regulus Therapeutics Inc

7RG0:FRA

Regulus Therapeutics Inc

Actions
  • Price (EUR)1.81
  • Today's Change-0.02 / -1.09%
  • Shares traded-1.00
  • 1 Year change+37.12%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.

  • Revenue in USD (TTM)0.00
  • Net income in USD-31.37m
  • Incorporated2007
  • Employees28.00
  • Location
    Regulus Therapeutics IncSUITE 210, 3545 JOHN HOPKINS COURTSAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 202-6300
  • Fax+1 (302) 655-5049
  • Websitehttps://www.regulusrx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.